-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Prelude Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
- Prelude Therapeutics Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.4M, a 2.97% decline year-over-year.
- Prelude Therapeutics Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$143M, a 11.7% decline year-over-year.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2023 was -$132M, a 7.07% decline from 2022.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2022 was -$124M, a 8.62% decline from 2021.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2021 was -$114M, a 93.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)